Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...

Please provide your email address to receive an email when new articles are posted on . A novel chimeric antigen receptor T-cell therapy induced responses in the first 12 evaluable patients with ...

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.

Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group plc has entered into a non-exclusive licensing agreement with Twist ...

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, today announces a new fee-for-service development contract valued at £112,000 with a ...

Synthetic anion binders could one day help treat the chronic lung disease. A University at Buffalo-led research team has developed molecules that could help unclog thick, sticky mucus from the lungs ...